Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 3924
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 3  |  Issue : 1  |  Page : 26-31

Can we consider metastatic colon cancer in the ambit of chronic disease in present scenario? Experience of a tertiary care centre from India


1 Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India
2 Department of General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India
3 Department of Radiology, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India

Correspondence Address:
Tapesh Bhattacharyya
Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh - 160 012, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-0513.125790

Rights and Permissions

Background: Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and it is ranked the third most common globally. Nearly, one fourth of the CRC patients have metastasis at diagnosis and overall survival (OS) was not more than 6 months to 1 year. With availability of plethora of new chemotherapeutic drugs, biological agents and advent of newer techniques like radiofrequency ablation or hyperthermic intraperitoneal chemotherapy, it is possible to achieve OS of more than 2 years. Materials and Methods: A retrospective review of 105 case files of colon cancer was done, who were treated in our institute between January 2006 and December 2010. Patients with carcinoma colon were evaluated by a team of surgeons and radiation oncologists and underwent treatment according to the protocol designed by the same team. Only the histologically proven adenocarcinomas of colon were included. Out of 105 patients, 61 (58%) patients had metastatic disease either synchronous or metachronous and those patients were taken up for analysis. Various treatment modalities used in this group of patients in our setting were analyzed and correlated with progression-free survival (PFS) and OS. Results: This heterogeneous group of metastatic colon cancer patients, which had been given various modalities of treatment, could be able to achieve a median survival of around 18 months and 2 year PFS of 28%. Conclusion: So metastatic colon cancer is no longer an acutely fatal disease, rather it is in the ambit of chronic disease.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2192    
    Printed45    
    Emailed1    
    PDF Downloaded95    
    Comments [Add]    

Recommend this journal